Gilead Sciences, Inc. $GILD Shares Sold by Tritonpoint Wealth LLC

Tritonpoint Wealth LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 66.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,382 shares of the biopharmaceutical company’s stock after selling 4,679 shares during the quarter. Tritonpoint Wealth LLC’s holdings in Gilead Sciences were worth $292,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the third quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $30,000. MTM Investment Management LLC raised its stake in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares in the last quarter. Millstone Evans Group LLC lifted its position in Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 118 shares during the last quarter. Finally, Y.D. More Investments Ltd acquired a new position in Gilead Sciences in the third quarter valued at $37,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD opened at $139.71 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The firm has a 50-day simple moving average of $145.09 and a 200-day simple moving average of $129.53. The company has a market capitalization of $173.41 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 1.83 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a $0.82 dividend. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the insider directly owned 131,779 shares of the company’s stock, valued at $19,006,485.17. This trade represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the transaction, the chief financial officer owned 179,191 shares in the company, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 299,280 shares of company stock worth $42,820,550 over the last three months. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of a number of research analyst reports. Cantor Fitzgerald lifted their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Scotiabank upped their target price on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 11th. Royal Bank Of Canada raised their price target on Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.